Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: Clin Cancer Res. 2017 Aug 30;23(22):6833–6845. doi: 10.1158/1078-0432.CCR-17-1087

Table 2.

Adverse event profile of MVA-brachyury-TRICOM

CTC term Grade 1 Grade 2 Grade 3 All Grades
# distinct
patients		 % of all
patients
(n=38)		 # of
Events		 Events as
% of doses
given
(n=107)		 # distinct
patients		 % of all
patients
(n=38)		 # of
events		 Events as
% of
doses
given
(n=107)		 # distinct
patients		 % of all
patients
(n=38)		 # of
events		 Events as
% of doses
given
(n=107)		 # distinct
patients		 % of all
patients
(n=38)		 # of
events		 Events as
% of
doses
given
(n=107)
Aspartate aminotransferase increased 1 2.6 1 0.9 0 0 0 0 0 0 0 0 1 2.6 1 0.9
Diarrhea 2 5.3 3 2.8 0 0 0 0 1 2.6 1 0.9 3 7.9 4 3.7
Fatigue 1 2.6 1 0.9 0 0 0 0 0 0 0 0 1 2.6 1 0.9
Fever 7 18.4 9 8.4 1 2.6 1 0.9 0 0 0 0 8 21.1 10 9.3
Flu like symptoms 15 39.5 23 21.5 0 0 0 0 0 0 0 0 15 39.5 23 21.5
Headache 1 2.6 1 0.9 0 0 0 0 0 0 0 0 1 2.6 1 0.9
Injection site reaction 21 55.3 32 29.9 19 50.0 26 24.3 0 0 0 0 30 78.9 58 54.2
Pruritus 1 2.6 1 0.9 0 0 0 0 0 0 0 0 1 2.6 1 0.9
Rash acneiform 1 2.6 1 0.9 0 0 0 0 0 0 0 0 1 2.6 1 0.9